Once you have established biologic efficacy and safety in early clinical material, your company’s real challenges are only beginning. Replicating the synthesis and bioanalysis of your biologic at different settings and among licensing or manufacturing partners introduces the risk of facility-based errors. And in order to commercialize your biologic, production volumes must be upscaled so intensely that new problems not encountered at smaller clinical volumes may severely hinder your timelines.
ExL Events’ 2nd annual Technology Transfer for Biologics conference, taking place October 5-6, 2015 in Boston, recognizes that every instance of technology transfer succeeds or fails based on transparency of communications and the skill of the project manager. Exclusive case studies from industry leaders can help you guarantee biologic quality and accelerate to commercial stages after method transfer. No other event focuses so specifically on the essential skill sets required for team-based biologics quality assurance during and after method transfer!